\-\ Texto\\:\\ \ \(0\)\
\-\ gen\\ \\-\\ cachectic\\ male\\,\\ lying\\ in\\ bed\\,\\ awake\\,\\ alert\\,\\ oriented\\ x3\ \(0\)\
\-\ heent\\ \\-\\ mmm\\,\\ perrl\\,\\ anicteric\\,\\ throat\\ non\\-erythematous\ \(0\)\
\-\ neck\\ \\-\\ supple\\,\\ no\\ palpable\\ lns\ \(0\)\
\-\ cv\\ \\-\\ rrr\\,\\ s1\\ s2\\ nml\\,\\ no\\ murmurs\ \(0\)\
\-\ resp\\ \\-\\ ctab\\,\\ no\\ crackles\\ or\\ wheezes\\,\\ r\\ hemidiaphragm\\ mildly\\ elevated\\ \ \(0\)\
\-\ abd\\ \\-\\ firm\\,\\ significantly\\ distended\\,\\ mildly\\ tender\\,\\ bs\\+\\ \ \(0\)\
\-\ ext\\ \\-\\ hands\\ and\\ feet\\ cold\\ to\\ touch\\,\\ 2\\+\\ edema\\ bilaterally\\,\\ pulses\\ 2\\+\\ bilaterally\\,\\ cap\\ refil\\ 2\\+\\ sec\ \(0\)\
\-\ neuro\\ \\-\\ cns\\ grossly\\ intact\\,\\ \\ strength\\/sensory\\ intact\\,\\ reflexes\\ 2\\+\\ bilaterally\ \(0\)\
\-\ s\\/p\\ surgical\\ resection\\ of\\ mass\\ without\\ symptoms\\ or\\ recurrence\\ to\\ date\\ \\(1\\ month\\)\\.\ \(0\)\
\-\ ct\\ abd\\/pelvis\ \(0\)\
\-\ 1\\.\\ there\\ is\\ a\\ massive\\ low\\ density\\ soft\\ tissue\\ mass\\ comprising\\ the\\ majority\\ of\\ the\\ anterior\\ and\\ mid\\ abdomen\\ as\\ well\\ as\\ the\\ pelvis\\.\\ the\\ mass\\ demonstrates\\ enhancing\\ septations\\.\\ it\\ is\\ predominantly\\ low\\ density\\.\\ some\\ of\\ the\\ areas\\ of\\ the\\ mass\\ more\\ centrally\\ are\\ lower\\ density\\ than\\ the\\ more\\ peripheral\\ portions\\ of\\ the\\ mass\\.\\ the\\ mass\\ almost\\ certainly\\ is\\ malignant\\.\\ tissue\\ sampling\\ is\\ recommended\\.\\ in\\ the\\ right\\ abdomen\\ there\\ is\\ small\\ low\\ density\\ area\\ which\\ may\\ represent\\ loculated\\ ascites\\ or\\ another\\ component\\ of\\ the\\ soft\\ tissue\\ mass\\ as\\ described\\ above\\.\ \(0\)\
\-\ 2\\.\\ there\\ is\\ a\\ small\\ amount\\ of\\ abdominal\\ and\\ pelvic\\ ascites\\ which\\ may\\ be\\ malignant\\ as\\ well\\.\\ \ \(0\)\
\-\ 3\\.\\ there\\ are\\ bilateral\\ pleural\\ effusions\\ and\\ dense\\ consolidation\\ in\\ the\\ lung\\ bases\\.\ \(0\)\
\-\ 4\\.\\ the\\ gallbladder\\ is\\ distended\\ and\\ there\\ is\\ a\\ small\\ amount\\ of\\ pericholecystic\\ fluid\\.\\ this\\ is\\ nonspecific\\.\ \(0\)\
\-\ pleomorphic\\ liposarcoma\ \(1\)\
\-\ malignant\\ neoplasm\ \(11\)\
\-\ 44\\ year\\-old\\ male\\ with\\ hx\\ of\\ h\\.\\ pylori\\ and\\ gastric\\ ulcers\\,\\ admitted\\ for\\ pre\\-op\\ treatment\\.\\ \\ patient\\ presented\\ to\\ outside\\ hospital\\ for\\ abdominal\\ mass\\ and\\ dysuria\\ 12\\/05\\,\\ imaging\\ followed\\ by\\ needle\\ biopsy\\ which\\ was\\ diagnosed\\ as\\ a\\ \\"gastrointestinal\\ stromal\\ tumor\\"\\.\\ \\ surgery\\ consult\\ at\\ that\\ time\\ suggested\\ neo\\-adjuvant\\ therapy\\ to\\ shrink\\ the\\ tumor\\ before\\ consideration\\ of\\ surgery\\.\\ \\ pt\\ took\\ gleevac\\ for\\ 2\\ months\\ with\\ no\\ effect\\ on\\ tumor\\ growth\\.\\ was\\ then\\ switched\\ to\\ sutant\\ for\\ 1\\ month\\,\\ which\\ he\\ stopped\\ a\\ few\\ days\\ prior\\ to\\ admission\\ because\\ of\\ nausea\\ and\\ vomiting\\.\\ \\ \\ pain\\ progressed\\ from\\ dysuria\\ to\\ diffuse\\ abdominal\\ pain\\ over\\ the\\ first\\ month\\,\\ but\\ is\\ currently\\ well\\ controlled\\ on\\ oral\\ morphine\\.\\ \\ appetite\\ is\\ present\\,\\ but\\ pt\\ is\\ unable\\ to\\ eat\\ normal\\ volumes\\ of\\ food\\ because\\ of\\ nausea\\ and\\ vomiting\\.\\ \\ according\\ to\\ family\\,\\ he\\ has\\ lost\\ 20\\+\\ lbs\\ since\\ the\\ onset\\ of\\ symptoms\\ 8\\ months\\ ago\\.\\ \\ \\ mild\\ pain\\ in\\ legs\\ and\\ sob\\ while\\ supine\\.\ \(0\)\
\-\ ros\\:\\ \\(\\+\\)\\ wt\\.\\ loss\\ of\\ 20\\+\\ lbs\\,\\ intermittent\\ sob\\ while\\ supine\\,\\ sometimes\\ sees\\ flashing\\ lights\\,\\ significant\\ weakness\\ and\\ fatigue\\,\\ mild\\ dysuria\\,\\ n\\/v\\,\\ reflux\\,\\ constipation\\ \\(d\\/t\\ narcotics\\)\\,\\ pain\\ in\\ legs\\ and\\ edema\\.\ \(0\)\
\-\ no\\ fevers\\,\\ chills\\,\\ cough\\,\\ hemoptysis\\.\\ \\ \ \(0\)\
\-\ no\\ chest\\ pain\\,\\ palpitations\\,\\ dyspnea\\ on\\ exertion\\.\\ \\ \ \(0\)\
\-\ no\\ diarrhea\\,\\ melena\\/brbpr\\.\\ \ \(0\)\
\-\ no\\ hematuria\\.\\ \\ \ \(0\)\
\-\ no\\ headache\\,\\ numbness\\,\\ lightheadedness\ \(0\)\
\-\ pmh\\:\\ gastric\\ ulcers\\,\\ h\\.\\ pylori\\ 2002\ \(0\)\
\-\ psh\\:\\ none\ \(0\)\
\-\ liposarcoma\\ is\\ a\\ malignancy\\ of\\ fat\\ cells\\.\\ in\\ adults\\,\\ it\\ is\\ the\\ most\\ common\\ soft\\ tissue\\ sarcoma\\.\\ liposarcoma\\ normally\\ appears\\ as\\ a\\ slowly\\ enlarging\\,\\ painless\\,\\ nonulcerated\\ submucosal\\ mass\\ in\\ a\\ middle\\-aged\\ person\\,\\ but\\ some\\ lesions\\ grow\\ rapidly\\ and\\ become\\ ulcerated\\ early\\.\\ virchow\\ first\\ described\\ liposarcoma\\ in\\ the\\ 1860s\\.\\ \ \(0\)\
\-\ the\\ development\\ of\\ a\\ liposarcoma\\ from\\ a\\ preexisting\\ benign\\ lipoma\\ is\\ rare\\.\\ most\\ cases\\ arise\\ de\\ novo\\.\\ liposarcomas\\ most\\ frequently\\ arise\\ from\\ the\\ deep\\-seated\\ stroma\\ rather\\ than\\ the\\ submucosal\\ or\\ subcutaneous\\ fat\\.\\ the\\ most\\ recent\\ world\\ health\\ organization\\ classification\\ of\\ soft\\ tissue\\ tumors\\ recognizes\\ 5\\ categories\\ of\\ liposarcomas\\:\\ \\(1\\)\\ well\\ differentiated\\,\\ which\\ includes\\ the\\ adipocytic\\,\\ sclerosing\\,\\ and\\ inflammatory\\ subtypes\\;\\ \\(2\\)\\ dedifferentiated\\;\\ \\(3\\)\\ myxoid\\;\\ \\(4\\)\\ round\\ cell\\;\\ and\\ \\(5\\)\\ pleomorphic\\.\\ \ \(0\)\
\-\ the\\ anatomical\\ distribution\\ of\\ liposarcoma\\ appears\\ to\\ be\\ partly\\ related\\ to\\ the\\ histologic\\ type\\.\\ well\\-differentiated\\ liposarcoma\\ tends\\ to\\ occur\\ in\\ deep\\ soft\\ tissues\\ of\\ both\\ the\\ limbs\\ and\\ the\\ retroperitoneum\\.\\ myxoid\\ and\\/or\\ round\\-cell\\ liposarcomas\\ and\\ pleomorphic\\ liposarcomas\\ have\\ a\\ striking\\ predilection\\ for\\ the\\ limbs\\,\\ and\\ dedifferentiated\\ liposarcoma\\ occurs\\ predominantly\\ in\\ the\\ retroperitoneum\\.\\ although\\ any\\ liposarcoma\\ subtype\\ occasionally\\ arises\\ in\\ the\\ subcutis\\,\\ involvement\\ of\\ the\\ dermis\\ appears\\ to\\ be\\ exceedingly\\ rare\\.\ \(0\)\
\-\ the\\ overall\\ 5\\-year\\ survival\\ rate\\ of\\ patients\\ with\\ deep\\ high\\-grade\\ liposarcoma\\ is\\ less\\ than\\ 50\\%\\.\\ \ \(0\)\
\-\ metastases\\ are\\ common\\,\\ especially\\ in\\ poorly\\ differentiated\\ liposarcomas\\.\\ the\\ lungs\\ and\\ the\\ liver\\ are\\ the\\ most\\ common\\ sites\\ of\\ metastasis\\.\\ \ \(0\)\
\-\ primary\\ cutaneous\\ liposarcoma\\ has\\ an\\ indolent\\ course\\.\\ \ \(0\)\
\-\ no\\ association\\ with\\ race\\ or\\ geography\\ is\\ known\\.\\ liposarcomas\\ are\\ slightly\\ more\\ common\\ in\\ males\\ than\\ in\\ females\\.\\ \ \(0\)\
\-\ the\\ mean\\ patient\\ age\\ at\\ onset\\ is\\ 50\\ years\\.\\ \ \(0\)\
\-\ although\\ liposarcomas\\ account\\ for\\ about\\ 17\\%\\ of\\ all\\ soft\\ tissue\\ sarcomas\\,\\ they\\ are\\ involved\\ in\\ only\\ 4\\%\\ of\\ childhood\\ soft\\ tissue\\ sarcomas\\.\\ cases\\ of\\ liposarcoma\\ are\\ reported\\ in\\ young\\ adults\\ and\\ teenagers\\,\\ but\\ cases\\ in\\ children\\ are\\ rare\\.\\ \ \(0\)\
\-\ in\\ the\\ case\\ of\\ well\\-differentiated\\ liposarcoma\\,\\ grade\\ provides\\ no\\ incremental\\ information\\ over\\ other\\ histological\\ subtypes\\ in\\ terms\\ of\\ response\\ to\\ therapy\\.\\ in\\ myxoid\\/round\\ cell\\ liposarcoma\\,\\ the\\ presence\\ of\\ a\\ round\\ cell\\ component\\ may\\ be\\ an\\ adverse\\ prognostic\\ sign\\.\\ tumor\\ site\\,\\ a\\ high\\ proliferative\\ fraction\\ noted\\ with\\ mib\\-1\\ labeling\\,\\ and\\ tp53\\ missense\\ mutations\\ are\\ also\\ adverse\\ prognostic\\ factors\\ in\\ myxoid\\/round\\ cell\\ tumors\\.\ \(0\)\
\-\ the\\ prognosis\\ is\\ affected\\ by\\ the\\ type\\ of\\ liposarcoma\\ present\\.\ \(0\)\
\-\ the\\ well\\-differentiated\\ type\\ and\\ most\\ myxoid\\ types\\ have\\ favorable\\ prognoses\\,\\ with\\ 100\\%\\ and\\ 88\\%\\ 5\\-year\\ survival\\ rates\\,\\ respectively\\.\\ however\\,\\ these\\ tumors\\ are\\ poorly\\ circumscribed\\ and\\ locally\\ recur\\ after\\ incomplete\\ excision\\.\\ although\\ they\\ rarely\\ metastasize\\,\\ repeated\\ local\\ recurrences\\ may\\ cause\\ the\\ tumor\\ to\\ evolve\\ into\\ a\\ higher\\ grade\\ of\\ sarcoma\\ or\\ to\\ dedifferentiate\\,\\ in\\ which\\ case\\ metastasis\\ is\\ possible\\.\ \(0\)\
\-\ the\\ form\\ that\\ a\\ dermatologist\\ is\\ most\\ likely\\ to\\ examine\\ at\\ biopsy\\ is\\ 1\\ of\\ the\\ 3\\ subtypes\\ of\\ a\\ well\\-differentiated\\ liposarcoma\\,\\ that\\ is\\,\\ the\\ lipomalike\\ liposarcoma\\ or\\ atypical\\ lipoma\\;\\ the\\ other\\ 2\\,\\ inflammatory\\ and\\ sclerosing\\,\\ are\\ less\\ likely\\.\\ the\\ clinical\\ outcome\\ of\\ this\\ subtype\\ is\\ best\\ predicted\\ by\\ the\\ anatomical\\ location\\.\\ in\\ the\\ subcutis\\,\\ lipomalike\\ liposarcomas\\ are\\ often\\ cured\\ with\\ local\\ excision\\.\\ lipomalike\\ liposarcomas\\ rarely\\ recur\\,\\ and\\ they\\ do\\ not\\ metastasize\\.\\ use\\ of\\ the\\ term\\ atypical\\ lipomatous\\ tumor\\,\\ a\\ less\\ serious\\ designation\\ for\\ atypical\\ lipoma\\,\\ has\\ been\\ suggested\\.\ \(0\)\
\-\ round\\-cell\\ and\\ poorly\\ differentiated\\ types\\ have\\ a\\ poor\\ prognosis\\.\\ each\\ has\\ a\\ 5\\-year\\ survival\\ rate\\ of\\ about\\ 50\\%\\ because\\ they\\ recur\\ locally\\ and\\ tend\\ to\\ metastasize\\ quickly\\ and\\ widely\\.\\ the\\ lungs\\ are\\ particularly\\ affected\\.\ \(0\)\
\-\ despite\\ high\\-grade\\ morphology\\,\\ cutaneous\\ liposarcomas\\ have\\ a\\ favorable\\ clinical\\ prognosis\\.\ \(0\)\
\-\ \\ \\ \ \(31891\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ allen\\ pw\\,\\ strungs\\ i\\,\\ maccormac\\ lb\\.\\ atypical\\ subcutaneous\\ fatty\\ tumors\\:\\ a\\ review\\ of\\ 37\\ referred\\ cases\\.\\ pathology\\ 1998\\;30\\(2\\)\\:\\ 123\\-35\\.\\ \ \(0\)\
\-\ 2\\.\\ antonescu\\ cr\\.\\ the\\ role\\ of\\ genetic\\ testing\\ in\\ soft\\ tissue\\ sarcoma\\.\\ histopathology\\ 2006\\;48\\(1\\)\\:13\\-21\\.\\ \ \(0\)\
\-\ azumi\\ n\\,\\ curtis\\ j\\,\\ kempson\\ rl\\,\\ hendrickson\\ mr\\.\\ atypical\\ and\\ malignant\\ neoplasms\\ showing\\ lipomatous\\ differentiation\\.\\ a\\ study\\ of\\ 111\\ cases\\.\\ am\\ j\\ surg\\ pathol\\ 1987\\;11\\(3\\)\\:161\\-83\\.\\ \ \(0\)\
\-\ 3\\.\\ binh\\ mb\\,\\ sastre\\-garau\\ x\\,\\ guillou\\ l\\,\\ et\\ al\\.\\ mdm2\\ and\\ cdk4\\ immunostainings\\ are\\ useful\\ adjuncts\\ in\\ diagnosing\\ well\\-differentiatedand\\ dedifferentiated\\ liposarcoma\\ subtypes\\:\\ a\\ comparative\\ analysis\\ of\\ 559\\ soft\\ tissue\\ neoplasms\\ with\\ geneticdata\\.\\ am\\ j\\ surg\\ pathol\\ 2005\\;29\\(10\\)\\:1340\\-7\\.\\ \ \(0\)\
\-\ 4\\.\\ dei\\ tos\\ ap\\,\\ mentzel\\ t\\,\\ fletcher\\ cd\\:\\ primary\\ liposarcoma\\ of\\ the\\ skin\\:\\ a\\ rare\\ neoplasm\\ with\\ unusual\\ high\\ grade\\ features\\.\\ am\\ j\\ dermatopathol\\ 1998\\;20\\(4\\)\\:332\\-8\\.\\ \ \(0\)\
\-\ 5\\.\\ deyrup\\ at\\,\\ weiss\\ sw\\:\\ grading\\ of\\ soft\\ tissue\\ sarcomas\\:\\ the\\ challenge\\ of\\ providing\\ precise\\ informationin\\ an\\ imprecise\\ world\\.\\ histopathology\\ 2006\\;48\\(1\\)\\:42\\-50\\.\\ \ \(0\)\
\-\ 6\\.\\ enzinger\\ fm\\,\\ weiss\\ sw\\.\\ liposarcoma\\.\\ in\\:\\ enzinger\\ and\\ weiss\\'s\\ soft\\ tissue\\ tumors\\.\\ 3rd\\ ed\\.\\ mosby\\-year\\ book\\;\\ 1995\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ liposarcoma\\:\\ 0\\.43080616049958637\ \(0\)\
\-\ liposarcomas\\:\\ 0\\.3220236507120708\ \(0\)\
\-\ the\\:\\ 0\\.21696801395158746\ \(0\)\
\-\ of\\:\\ 0\\.17338593334065053\ \(0\)\
\-\ and\\:\\ 0\\.1373105163094266\ \(0\)\
\-\ differentiated\\:\\ 0\\.13457553056868846\ \(0\)\
\-\ is\\:\\ 0\\.13234725635191089\ \(0\)\
\-\ in\\:\\ 0\\.13024085870839763\ \(0\)\
\-\ myxoid\\:\\ 0\\.1266666491008069\ \(0\)\
\-\ soft\\:\\ 0\\.1179216518497607\ \(0\)\
\-\ tissue\\:\\ 0\\.1161936762326063\ \(0\)\
\-\ are\\:\\ 0\\.10697146597835802\ \(0\)\
\-\ round\\:\\ 0\\.09899499181921063\ \(0\)\
\-\ lipomalike\\:\\ 0\\.09660709521362124\ \(0\)\
\-\ subtypes\\:\\ 0\\.0949513149533716\ \(0\)\
\-\ to\\:\\ 0\\.09061274407525596\ \(0\)\
\-\ well\\:\\ 0\\.08775096420730424\ \(0\)\
\-\ dedifferentiated\\:\\ 0\\.08690361531681468\ \(0\)\
\-\ weiss\\:\\ 0\\.08497283778129815\ \(0\)\
\-\ atypical\\:\\ 0\\.08259934545877627\ \(0\)\
\-\ sarcomas\\:\\ 0\\.07599998946048414\ \(0\)\
\-\ tumors\\:\\ 0\\.07404614692884612\ \(0\)\
\-\ metastasize\\:\\ 0\\.07394388552159735\ \(0\)\
\-\ most\\:\\ 0\\.07335686778076805\ \(0\)\
\-\ grade\\:\\ 0\\.07239884480445855\ \(0\)\
\-\ no\\:\\ 0\\.07202913627451059\ \(0\)\
\-\ recur\\:\\ 0\\.07121348621502871\ \(0\)\
\-\ mass\\:\\ 0\\.06922384252361372\ \(0\)\
\-\ cell\\:\\ 0\\.06911342885537106\ \(0\)\
\-\ dysuria\\:\\ 0\\.06904472209141448\ \(0\)\
\-\ cases\\:\\ 0\\.06771891385835281\ \(0\)\
\-\ enzinger\\:\\ 0\\.06440473014241416\ \(0\)\
\-\ tumor\\:\\ 0\\.06319479314390558\ \(0\)\
\-\ sw\\:\\ 0\\.061542157970707105\ \(0\)\
\-\ pleomorphic\\:\\ 0\\.06113175334192841\ \(0\)\
\-\ rare\\:\\ 0\\.06080440816126697\ \(0\)\
\-\ subcutis\\:\\ 0\\.05951113069257249\ \(0\)\
\-\ survival\\:\\ 0\\.058956110388915066\ \(0\)\
\-\ they\\:\\ 0\\.05755110861455945\ \(0\)\
\-\ malignant\\:\\ 0\\.0574155561176689\ \(0\)\
\-\ am\\:\\ 0\\.05702533285339854\ \(0\)\
\-\ 50\\:\\ 0\\.05625080917522124\ \(0\)\
\-\ or\\:\\ 0\\.05604054730635708\ \(0\)\
\-\ which\\:\\ 0\\.054937120032661456\ \(0\)\
\-\ poorly\\:\\ 0\\.054561872635840246\ \(0\)\
\-\ density\\:\\ 0\\.053409823707544136\ \(0\)\
\-\ prognosis\\:\\ 0\\.05316027639119867\ \(0\)\
\-\ lipomatous\\:\\ 0\\.05304214409470145\ \(0\)\
\-\ lipoma\\:\\ 0\\.0524005114887509\ \(0\)\
\-\ pathol\\:\\ 0\\.052369256926527476\ \(0\)\
\-\ world\\:\\ 0\\.05175495907102376\ \(0\)\
\-\ sarcoma\\:\\ 0\\.05067537065695115\ \(0\)\
\-\ retroperitoneum\\:\\ 0\\.05017957192299439\ \(0\)\
\-\ adverse\\:\\ 0\\.05017957192299439\ \(0\)\
\-\ pylori\\:\\ 0\\.04972393179288915\ \(0\)\
\-\ as\\:\\ 0\\.048536854931489355\ \(0\)\
\-\ locally\\:\\ 0\\.04814854464485977\ \(0\)\
\-\ subtype\\:\\ 0\\.0474756574766858\ \(0\)\
\-\ limbs\\:\\ 0\\.047161829292770525\ \(0\)\
\-\ prognostic\\:\\ 0\\.047161829292770525\ \(0\)\
\-\ deep\\:\\ 0\\.04702352456712694\ \(0\)\
\-\ favorable\\:\\ 0\\.04602981472760965\ \(0\)\
\-\ high\\:\\ 0\\.0457766678444714\ \(0\)\
\-\ common\\:\\ 0\\.04567840757794918\ \(0\)\
\-\ than\\:\\ 0\\.04565883731380901\ \(0\)\
\-\ anatomical\\:\\ 0\\.04483033234304747\ \(0\)\
\-\ submucosal\\:\\ 0\\.04461308530497874\ \(0\)\
\-\ appears\\:\\ 0\\.04423755814026764\ \(0\)\
\-\ 1998\\:\\ 0\\.0432549451950181\ \(0\)\
\-\ surg\\:\\ 0\\.04291048801877403\ \(0\)\
\-\ for\\:\\ 0\\.04272215592948794\ \(0\)\
\-\ ulcers\\:\\ 0\\.04242340030144565\ \(0\)\
\-\ sclerosing\\:\\ 0\\.04242340030144565\ \(0\)\
\-\ because\\:\\ 0\\.04221920810050325\ \(0\)\
\-\ cutaneous\\:\\ 0\\.04182218858807303\ \(0\)\
\-\ sob\\:\\ 0\\.04167955804698873\ \(0\)\
\-\ ascites\\:\\ 0\\.04153975205951617\ \(0\)\
\-\ lbs\\:\\ 0\\.04153975205951617\ \(0\)\
\-\ although\\:\\ 0\\.0411252700474361\ \(0\)\
\-\ less\\:\\ 0\\.04109721716351486\ \(0\)\
\-\ histopathology\\:\\ 0\\.040631717017316576\ \(0\)\
\-\ may\\:\\ 0\\.04053293183264999\ \(0\)\
\-\ type\\:\\ 0\\.04052464758879131\ \(0\)\
\-\ supine\\:\\ 0\\.04039237302331104\ \(0\)\
\-\ bilaterally\\:\\ 0\\.040288430564986724\ \(0\)\
\-\ have\\:\\ 0\\.04023679251934489\ \(0\)\
\-\ 2006\\:\\ 0\\.040160877803497315\ \(0\)\
\-\ there\\:\\ 0\\.040060903270590247\ \(0\)\
\-\ but\\:\\ 0\\.039829773875259704\ \(0\)\
\-\ legs\\:\\ 0\\.039613318867141166\ \(0\)\
\-\ 20\\:\\ 0\\.038972123029568505\ \(0\)\
\-\ subcutaneous\\:\\ 0\\.03836134574517643\ \(0\)\
\-\ suggested\\:\\ 0\\.037688458577002454\ \(0\)\
\-\ adults\\:\\ 0\\.03760868403715735\ \(0\)\
\-\ neoplasms\\:\\ 0\\.03752980085160399\ \(0\)\
\-\ abd\\:\\ 0\\.03745178932129691\ \(0\)\
\-\ types\\:\\ 0\\.03745178932129691\ \(0\)\
\-\ arise\\:\\ 0\\.03685691368343001\ \(0\)\
\-\ has\\:\\ 0\\.03679074352536308\ \(0\)\
\-\ month\\:\\ 0\\.03674747509559683\ \(0\)\
\-\ pain\\:\\ 0\\.03602758807396596\ \(0\)\
\-\ rarely\\:\\ 0\\.03592310557395913\ \(0\)\
\-\ with\\:\\ 0\\.03548649505796713\ \(0\)\
\-\ predominantly\\:\\ 0\\.03526727835365564\ \(0\)\
\-\ 48\\:\\ 0\\.03487957466142841\ \(0\)\
\-\ local\\:\\ 0\\.034667228679896925\ \(0\)\
\-\ low\\:\\ 0\\.034662994462963205\ \(0\)\
\-\ component\\:\\ 0\\.03451205822138012\ \(0\)\
\-\ distended\\:\\ 0\\.03441047414276837\ \(0\)\
\-\ gastric\\:\\ 0\\.033923386425439996\ \(0\)\
\-\ more\\:\\ 0\\.033170986098597796\ \(0\)\
\-\ affected\\:\\ 0\\.03312328911909069\ \(0\)\
\-\ abdominal\\:\\ 0\\.03303926851138153\ \(0\)\
\-\ described\\:\\ 0\\.03267553282191904\ \(0\)\
\-\ be\\:\\ 0\\.032674005856091135\ \(0\)\
\-\ mildly\\:\\ 0\\.0325195049984539\ \(0\)\
\-\ amount\\:\\ 0\\.032217428048165665\ \(0\)\
\-\ lns\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ refil\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ sutant\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ sees\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ flashing\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ nonulcerated\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ 1860s\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ recognizes\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ adipocytic\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ geography\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ incremental\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ tp53\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ missense\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ dedifferentiate\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ pw\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ strungs\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ maccormac\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ antonescu\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ azumi\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ kempson\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ hendrickson\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ binh\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ guillou\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ mdm2\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ cdk4\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ immunostainings\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ 559\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ geneticdata\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ dei\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ mentzel\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ fletcher\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ dermatopathol\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ deyrup\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ informationin\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ imprecise\\:\\ 0\\.03220236507120708\ \(0\)\
\-\ excision\\:\\ 0\\.03175255315983282\ \(0\)\
\-\ small\\:\\ 0\\.031160981578933072\ \(0\)\
\-\ nausea\\:\\ 0\\.03093640624762788\ \(0\)\
\-\ gleevac\\:\\ 0\\.030771078985353553\ \(0\)\
\-\ lights\\:\\ 0\\.030771078985353553\ \(0\)\
\-\ prognoses\\:\\ 0\\.030771078985353553\ \(0\)\
\-\ rate\\:\\ 0\\.030517471484512188\ \(0\)\
\-\ at\\:\\ 0\\.03042297731900598\ \(0\)\
\-\ about\\:\\ 0\\.030149533993522465\ \(0\)\
\-\ vomiting\\:\\ 0\\.02979982581543098\ \(0\)\
\-\ preexisting\\:\\ 0\\.029755565346286244\ \(0\)\
\-\ curtis\\:\\ 0\\.029755565346286244\ \(0\)\
\-\ adjuncts\\:\\ 0\\.029755565346286244\ \(0\)\
\-\ tos\\:\\ 0\\.029755565346286244\ \(0\)\
\-\ lungs\\:\\ 0\\.02972152588169821\ \(0\)\
\-\ metastasis\\:\\ 0\\.0295168746929267\ \(0\)\
\-\ intact\\:\\ 0\\.029148444754571075\ \(0\)\
\-\ pt\\:\\ 0\\.02898287669232161\ \(0\)\
\-\ lightheadedness\\:\\ 0\\.02896787177227156\ \(0\)\
\-\ organization\\:\\ 0\\.02896787177227156\ \(0\)\
\-\ teenagers\\:\\ 0\\.02896787177227156\ \(0\)\
\-\ designation\\:\\ 0\\.02896787177227156\ \(0\)\
\-\ fm\\:\\ 0\\.02896787177227156\ \(0\)\
\-\ novo\\:\\ 0\\.028324279260432714\ \(0\)\
\-\ partly\\:\\ 0\\.028324279260432714\ \(0\)\
\-\ indolent\\:\\ 0\\.028324279260432714\ \(0\)\
\-\ dermatologist\\:\\ 0\\.028324279260432714\ \(0\)\
\-\ examine\\:\\ 0\\.028324279260432714\ \(0\)\
\-\ biopsy\\:\\ 0\\.028229689669249016\ \(0\)\
\-\ pelvis\\:\\ 0\\.028166933952410395\ \(0\)\
\-\ exceedingly\\:\\ 0\\.027780129545082216\ \(0\)\
\-\ allen\\:\\ 0\\.027780129545082216\ \(0\)\
\-\ rl\\:\\ 0\\.027780129545082216\ \(0\)\
\-\ mb\\:\\ 0\\.027780129545082216\ \(0\)\
\-\ book\\:\\ 0\\.027780129545082216\ \(0\)\
\-\ neoplasm\\:\\ 0\\.027492153776674907\ \(0\)\
\-\ shrink\\:\\ 0\\.02730876562136541\ \(0\)\
\-\ eat\\:\\ 0\\.02730876562136541\ \(0\)\
\-\ predicted\\:\\ 0\\.02730876562136541\ \(0\)\
\-\ inflammatory\\:\\ 0\\.027232020130852932\ \(0\)\
\-\ first\\:\\ 0\\.0271775027042852\ \(0\)\
\-\ cachectic\\:\\ 0\\.026892993174579185\ \(0\)\
\-\ labeling\\:\\ 0\\.026892993174579185\ \(0\)\
\-\ mutations\\:\\ 0\\.026892993174579185\ \(0\)\
\-\ evolve\\:\\ 0\\.026892993174579185\ \(0\)\
\-\ comparative\\:\\ 0\\.026892993174579185\ \(0\)\
\-\ narcotics\\:\\ 0\\.026521072047350724\ \(0\)\
\-\ cured\\:\\ 0\\.026521072047350724\ \(0\)\
\-\ challenge\\:\\ 0\\.026521072047350724\ \(0\)\
\-\ that\\:\\ 0\\.026215227851483777\ \(0\)\
\-\ comprising\\:\\ 0\\.026184628463263738\ \(0\)\
\-\ switched\\:\\ 0\\.026184628463263738\ \(0\)\
\-\ virchow\\:\\ 0\\.026184628463263738\ \(0\)\
\-\ 1987\\:\\ 0\\.026184628463263738\ \(0\)\
\-\ while\\:\\ 0\\.02602740881641871\ \(0\)\
\-\ mmm\\:\\ 0\\.02587747953551188\ \(0\)\
\-\ recurrences\\:\\ 0\\.02587747953551188\ \(0\)\
\-\ cd\\:\\ 0\\.02587747953551188\ \(0\)\
\-\ grading\\:\\ 0\\.02587747953551188\ \(0\)\
\-\ onset\\:\\ 0\\.025860211146035077\ \(0\)\
\-\ by\\:\\ 0\\.02565315252037524\ \(0\)\
\-\ anicteric\\:\\ 0\\.025594929911694157\ \(0\)\
\-\ sampling\\:\\ 0\\.025594929911694157\ \(0\)\
\-\ morphine\\:\\ 0\\.025594929911694157\ \(0\)\
\-\ race\\:\\ 0\\.025594929911694157\ \(0\)\
\-\ precise\\:\\ 0\\.025594929911694157\ \(0\)\
\-\ clinical\\:\\ 0\\.025522910555967313\ \(0\)\
\-\ some\\:\\ 0\\.025339157177200488\ \(0\)\
\-\ ulcerated\\:\\ 0\\.02533332982016138\ \(0\)\
\-\ proliferative\\:\\ 0\\.02533332982016138\ \(0\)\
\-\ x3\\:\\ 0\\.025089785961497194\ \(0\)\
\-\ fat\\:\\ 0\\.025052071342148045\ \(0\)\
\-\ primary\\:\\ 0\\.024763333376905172\ \(0\)\
\-\ perrl\\:\\ 0\\.02464796184053245\ \(0\)\
\-\ providing\\:\\ 0\\.02464796184053245\ \(0\)\
\-\ abdomen\\:\\ 0\\.024573026122357393\ \(0\)\
\-\ certainly\\:\\ 0\\.02444619344965835\ \(0\)\
\-\ lb\\:\\ 0\\.0242553369247505\ \(0\)\
\-\ sec\\:\\ 0\\.024074272322429886\ \(0\)\
\-\ likely\\:\\ 0\\.024065938471941748\ \(0\)\
\-\ edema\\:\\ 0\\.024019491122448243\ \(0\)\
\-\ from\\:\\ 0\\.02399188208599144\ \(0\)\
\-\ nml\\:\\ 0\\.023902043734307852\ \(0\)\
\-\ categories\\:\\ 0\\.023902043734307852\ \(0\)\
\-\ striking\\:\\ 0\\.023902043734307852\ \(0\)\
\-\ fraction\\:\\ 0\\.023902043734307852\ \(0\)\
\-\ he\\:\\ 0\\.023847985401404967\ \(0\)\
\-\ stroma\\:\\ 0\\.0237378287383429\ \(0\)\
\-\ quickly\\:\\ 0\\.0237378287383429\ \(0\)\
\-\ volumes\\:\\ 0\\.023580914646385263\ \(0\)\
\-\ ros\\:\\ 0\\.023580914646385263\ \(0\)\
\-\ palpitations\\:\\ 0\\.023580914646385263\ \(0\)\
\-\ psh\\:\\ 0\\.023580914646385263\ \(0\)\
\-\ months\\:\\ 0\\.02344193885366575\ \(0\)\
\-\ awake\\:\\ 0\\.0232865787484152\ \(0\)\
\-\ tends\\:\\ 0\\.0232865787484152\ \(0\)\
\-\ predilection\\:\\ 0\\.0232865787484152\ \(0\)\
\-\ widely\\:\\ 0\\.0232865787484152\ \(0\)\
\-\ resp\\:\\ 0\\.023148130186773322\ \(0\)\
\-\ took\\:\\ 0\\.023148130186773322\ \(0\)\
\-\ therapy\\:\\ 0\\.023139247737907338\ \(0\)\
\-\ an\\:\\ 0\\.023100187617266642\ \(0\)\
\-\ grow\\:\\ 0\\.023014907363804824\ \(0\)\
\-\ loculated\\:\\ 0\\.022886530095240547\ \(0\)\
\-\ terms\\:\\ 0\\.022886530095240547\ \(0\)\
\-\ mild\\:\\ 0\\.022829418656904504\ \(0\)\
\-\ person\\:\\ 0\\.022762658233579123\ \(0\)\
\-\ dermis\\:\\ 0\\.022762658233579123\ \(0\)\
\-\ serious\\:\\ 0\\.022762658233579123\ \(0\)\
\-\ cap\\:\\ 0\\.022642986236576356\ \(0\)\
\-\ diagnosing\\:\\ 0\\.022642986236576356\ \(0\)\
\-\ pericholecystic\\:\\ 0\\.022527238626669492\ \(0\)\
\-\ stopped\\:\\ 0\\.022527238626669492\ \(0\)\
\-\ histologic\\:\\ 0\\.022527238626669492\ \(0\)\
\-\ wt\\:\\ 0\\.022415166171523736\ \(0\)\
\-\ over\\:\\ 0\\.022393362371973733\ \(0\)\
\-\ mean\\:\\ 0\\.022201162115611614\ \(0\)\
\-\ histological\\:\\ 0\\.022201162115611614\ \(0\)\
\-\ ctab\\:\\ 0\\.022098836521225858\ \(0\)\
\-\ provides\\:\\ 0\\.022098836521225858\ \(0\)\
\-\ symptoms\\:\\ 0\\.022034911193807134\ \(0\)\
\-\ supple\\:\\ 0\\.021999393724737516\ \(0\)\
\-\ stromal\\:\\ 0\\.021999393724737516\ \(0\)\
\-\ constipation\\:\\ 0\\.02190267573411908\ \(0\)\
\-\ 111\\:\\ 0\\.02190267573411908\ \(0\)\
\-\ septations\\:\\ 0\\.021808537199829666\ \(0\)\
\-\ de\\:\\ 0\\.021808537199829666\ \(0\)\
\-\ 1995\\:\\ 0\\.021716844100919792\ \(0\)\
\-\ surgery\\:\\ 0\\.021652278457719262\ \(0\)\
\-\ ext\\:\\ 0\\.02154030802497932\ \(0\)\
\-\ arises\\:\\ 0\\.02154030802497932\ \(0\)\
\-\ cold\\:\\ 0\\.021455244009387014\ \(0\)\
\-\ outcome\\:\\ 0\\.021455244009387014\ \(0\)\
\-\ morphology\\:\\ 0\\.021455244009387014\ \(0\)\
\-\ wheezes\\:\\ 0\\.021211700150722827\ \(0\)\
\-\ consult\\:\\ 0\\.021211700150722827\ \(0\)\
\-\ appetite\\:\\ 0\\.021134114921464425\ \(0\)\
\-\ exertion\\:\\ 0\\.021134114921464425\ \(0\)\
\-\ role\\:\\ 0\\.021134114921464425\ \(0\)\
\-\ lost\\:\\ 0\\.02105819832179473\ \(0\)\
\-\ hemidiaphragm\\:\\ 0\\.020983880085670207\ \(0\)\
\-\ controlled\\:\\ 0\\.020983880085670207\ \(0\)\
\-\ rates\\:\\ 0\\.020983880085670207\ \(0\)\
\-\ other\\:\\ 0\\.020914232227936515\ \(0\)\
\-\ bed\\:\\ 0\\.020911094294036515\ \(0\)\
\-\ progressed\\:\\ 0\\.020911094294036515\ \(0\)\
\-\ food\\:\\ 0\\.020911094294036515\ \(0\)\
\-\ repeated\\:\\ 0\\.020911094294036515\ \(0\)\
\-\ hemoptysis\\:\\ 0\\.020839779023494365\ \(0\)\
\-\ respectively\\:\\ 0\\.020839779023494365\ \(0\)\
\-\ cr\\:\\ 0\\.020839779023494365\ \(0\)\
\-\ crackles\\:\\ 0\\.020769876029758085\ \(0\)\
\-\ males\\:\\ 0\\.020769876029758085\ \(0\)\
\-\ massive\\:\\ 0\\.020701330461852484\ \(0\)\
\-\ bases\\:\\ 0\\.020701330461852484\ \(0\)\
\-\ classification\\:\\ 0\\.020701330461852484\ \(0\)\
\-\ present\\:\\ 0\\.02066520326100298\ \(0\)\
\-\ it\\:\\ 0\\.02061500518095014\ \(0\)\
\-\ 88\\:\\ 0\\.020568107638883986\ \(0\)\
\-\ tend\\:\\ 0\\.020568107638883986\ \(0\)\
\-\ account\\:\\ 0\\.02050333543940738\ \(0\)\
\-\ childhood\\:\\ 0\\.020377251113976137\ \(0\)\
\-\ consideration\\:\\ 0\\.020315858508658288\ \(0\)\
\-\ lying\\:\\ 0\\.020255515401141896\ \(0\)\
\-\ according\\:\\ 0\\.020255515401141896\ \(0\)\
\-\ females\\:\\ 0\\.020255515401141896\ \(0\)\
\-\ case\\:\\ 0\\.020232539990116486\ \(0\)\
\-\ throat\\:\\ 0\\.02019618651165552\ \(0\)\
\-\ rapidly\\:\\ 0\\.020137838310001318\ \(0\)\
\-\ cv\\:\\ 0\\.020023957923533484\ \(0\)\
\-\ health\\:\\ 0\\.019913636887837798\ \(0\)\
\-\ information\\:\\ 0\\.019913636887837798\ \(0\)\
\-\ gen\\:\\ 0\\.019859742927568536\ \(0\)\
\-\ centrally\\:\\ 0\\.019859742927568536\ \(0\)\
\-\ gastrointestinal\\:\\ 0\\.019859742927568536\ \(0\)\
\-\ slowly\\:\\ 0\\.019859742927568536\ \(0\)\
\-\ genetic\\:\\ 0\\.019859742927568536\ \(0\)\
\-\ touch\\:\\ 0\\.019754362390690776\ \(0\)\
\-\ incomplete\\:\\ 0\\.019754362390690776\ \(0\)\
\-\ sites\\:\\ 0\\.019652036796305023\ \(0\)\
\-\ differentiation\\:\\ 0\\.01955259399981668\ \(0\)\
\-\ fatigue\\:\\ 0\\.019503903768152055\ \(0\)\
\-\ s2\\:\\ 0\\.01936173747490883\ \(0\)\
\-\ murmurs\\:\\ 0\\.019315593212218037\ \(0\)\
\-\ grossly\\:\\ 0\\.019315593212218037\ \(0\)\
\-\ occasionally\\:\\ 0\\.019315593212218037\ \(0\)\
\-\ 2002\\:\\ 0\\.019270044375998958\ \(0\)\
\-\ useful\\:\\ 0\\.019225075795526923\ \(0\)\
\-\ portions\\:\\ 0\\.019136821553030457\ \(0\)\
\-\ fatty\\:\\ 0\\.019136821553030457\ \(0\)\
\-\ 2005\\:\\ 0\\.019136821553030457\ \(0\)\
\-\ hands\\:\\ 0\\.01909350830005848\ \(0\)\
\-\ pulses\\:\\ 0\\.01909350830005848\ \(0\)\
\-\ each\\:\\ 0\\.01909350830005848\ \(0\)\
\-\ diarrhea\\:\\ 0\\.01905072006914878\ \(0\)\
\-\ particularly\\:\\ 0\\.01900844428446618\ \(0\)\
\-\ significantly\\:\\ 0\\.01892538196205436\ \(0\)\
\-\ feet\\:\\ 0\\.01892538196205436\ \(0\)\
\-\ nonspecific\\:\\ 0\\.01892538196205436\ \(0\)\
\-\ effusions\\:\\ 0\\.018844229288501227\ \(0\)\
\-\ sometimes\\:\\ 0\\.018844229288501227\ \(0\)\
\-\ cns\\:\\ 0\\.018804342018578675\ \(0\)\
\-\ enlarging\\:\\ 0\\.018804342018578675\ \(0\)\
\-\ rrr\\:\\ 0\\.018764900425801995\ \(0\)\
\-\ neuro\\:\\ 0\\.018764900425801995\ \(0\)\
\-\ analysis\\:\\ 0\\.018725894660648456\ \(0\)\
\-\ needle\\:\\ 0\\.01868731519654359\ \(0\)\
\-\ painless\\:\\ 0\\.018649152815895124\ \(0\)\
\-\ date\\:\\ 0\\.018611398596873895\ \(0\)\
\-\ consolidation\\:\\ 0\\.018611398596873895\ \(0\)\
\-\ response\\:\\ 0\\.018574043900894142\ \(0\)\
\-\ alert\\:\\ 0\\.018537080360749376\ \(0\)\
\-\ overall\\:\\ 0\\.018500499869362964\ \(0\)\
\-\ 3rd\\:\\ 0\\.018392979298573527\ \(0\)\
\-\ normally\\:\\ 0\\.018357854771666075\ \(0\)\
\-\ hx\\:\\ 0\\.018323076304837246\ \(0\)\
\-\ chills\\:\\ 0\\.018323076304837246\ \(0\)\
\-\ majority\\:\\ 0\\.018288637145532995\ \(0\)\
\-\ higher\\:\\ 0\\.018288637145532995\ \(0\)\
\-\ firm\\:\\ 0\\.01825453073693165\ \(0\)\
\-\ on\\:\\ 0\\.01824454605347211\ \(0\)\
\-\ pmh\\:\\ 0\\.018220750710451494\ \(0\)\
\-\ oriented\\:\\ 0\\.018154145228238695\ \(0\)\
\-\ association\\:\\ 0\\.01812130791396315\ \(0\)\
\-\ almost\\:\\ 0\\.01808877325205022\ \(0\)\
\-\ testing\\:\\ 0\\.01808877325205022\ \(0\)\
\-\ unusual\\:\\ 0\\.01805653571448654\ \(0\)\
\-\ heent\\:\\ 0\\.017992930645398874\ \(0\)\
\-\ gallbladder\\:\\ 0\\.017992930645398874\ \(0\)\
\-\ male\\:\\ 0\\.01793093172216124\ \(0\)\
\-\ numbness\\:\\ 0\\.0178996216225289\ \(0\)\
\-\ become\\:\\ 0\\.017869058783737454\ \(0\)\
\-\ rather\\:\\ 0\\.017838758290145428\ \(0\)\
\-\ 44\\:\\ 0\\.01780871567622106\ \(0\)\
\-\ hematuria\\:\\ 0\\.01780871567622106\ \(0\)\
\-\ fevers\\:\\ 0\\.017778926589486748\ \(0\)\
\-\ dense\\:\\ 0\\.017749386786734683\ \(0\)\
\-\ dyspnea\\:\\ 0\\.017720092130399556\ \(0\)\
\-\ reflexes\\:\\ 0\\.017605285724558842\ \(0\)\
\-\ form\\:\\ 0\\.017605285724558842\ \(0\)\
\-\ s1\\:\\ 0\\.017577158198612653\ \(0\)\
\-\ 29\\:\\ 0\\.017549253026975322\ \(0\)\
\-\ despite\\:\\ 0\\.017521566721682067\ \(0\)\
\-\ unable\\:\\ 0\\.017439787330714204\ \(0\)\
\-\ reflux\\:\\ 0\\.017439787330714204\ \(0\)\
\-\ showing\\:\\ 0\\.0173863016737048\ \(0\)\
\-\ 37\\:\\ 0\\.017155165510870322\ \(0\)\
\-\ few\\:\\ 0\\.017081365209722765\ \(0\)\
\-\ distribution\\:\\ 0\\.017081365209722765\ \(0\)\
\-\ factors\\:\\ 0\\.01703300848326215\ \(0\)\
\-\ poor\\:\\ 0\\.016985305246103942\ \(0\)\
\-\ admission\\:\\ 0\\.016800688754338062\ \(0\)\
\-\ represent\\:\\ 0\\.016756004792759887\ \(0\)\
\-\ do\\:\\ 0\\.016690021828109622\ \(0\)\
\-\ development\\:\\ 0\\.016646708575137645\ \(0\)\
\-\ recurrence\\:\\ 0\\.016625249628633015\ \(0\)\
\-\ growth\\:\\ 0\\.016603920344227942\ \(0\)\
\-\ young\\:\\ 0\\.016603920344227942\ \(0\)\
\-\ frequently\\:\\ 0\\.01658271916440561\ \(0\)\
\-\ review\\:\\ 0\\.01658271916440561\ \(0\)\
\-\ 100\\:\\ 0\\.016519869091755256\ \(0\)\
\-\ admitted\\:\\ 0\\.016499165303201772\ \(0\)\
\-\ children\\:\\ 0\\.016499165303201772\ \(0\)\
\-\ another\\:\\ 0\\.016478582237133523\ \(0\)\
\-\ intermittent\\:\\ 0\\.0164581184938577\ \(0\)\
\-\ 17\\:\\ 0\\.01643777269788392\ \(0\)\
\-\ before\\:\\ 0\\.01627909493572762\ \(0\)\
\-\ metastases\\:\\ 0\\.01627909493572762\ \(0\)\
\-\ site\\:\\ 0\\.016240515471622752\ \(0\)\
\-\ best\\:\\ 0\\.01620235309097429\ \(0\)\
\-\ features\\:\\ 0\\.01620235309097429\ \(0\)\
\-\ outside\\:\\ 0\\.01616459887195306\ \(0\)\
\-\ involved\\:\\ 0\\.016145872112759124\ \(0\)\
\-\ oral\\:\\ 0\\.016127244175973308\ \(0\)\
\-\ ed\\:\\ 0\\.016108714024082833\ \(0\)\
\-\ references\\:\\ 0\\.016053700144442126\ \(0\)\
\-\ recommended\\:\\ 0\\.016017494844194843\ \(0\)\
\-\ al\\:\\ 0\\.0159995305009497\ \(0\)\
\-\ especially\\:\\ 0\\.015928573622796215\ \(0\)\
\-\ tissues\\:\\ 0\\.01587627657991641\ \(0\)\
\-\ occurs\\:\\ 0\\.01587627657991641\ \(0\)\
\-\ family\\:\\ 0\\.015841837420612157\ \(0\)\
\-\ pathology\\:\\ 0\\.01580773101201081\ \(0\)\
\-\ term\\:\\ 0\\.01579080059188632\ \(0\)\
\-\ et\\:\\ 0\\.01577395098553066\ \(0\)\
\-\ pelvic\\:\\ 0\\.015740491153692582\ \(0\)\
\-\ slightly\\:\\ 0\\.01570734550331786\ \(0\)\
\-\ includes\\:\\ 0\\.01565820337562379\ \(0\)\
\-\ circumscribed\\:\\ 0\\.015593726956098689\ \(0\)\
\-\ cells\\:\\ 0\\.015514753062058729\ \(0\)\
\-\ currently\\:\\ 0\\.01546820312381394\ \(0\)\
\-\ use\\:\\ 0\\.015407076300661576\ \(0\)\
\-\ related\\:\\ 0\\.015302587061813852\ \(0\)\
\-\ pleural\\:\\ 0\\.015158485999638005\ \(0\)\
\-\ malignancy\\:\\ 0\\.015074766996761232\ \(0\)\
\-\ 11\\:\\ 0\\.015074766996761232\ \(0\)\
\-\ cough\\:\\ 0\\.015033640483073379\ \(0\)\
\-\ skin\\:\\ 0\\.014979540024466628\ \(0\)\
\-\ referred\\:\\ 0\\.01489991290771549\ \(0\)\
\-\ hospital\\:\\ 0\\.014873764744974064\ \(0\)\
\-\ course\\:\\ 0\\.014873764744974064\ \(0\)\
\-\ occur\\:\\ 0\\.014809229385769222\ \(0\)\
\-\ ago\\:\\ 0\\.014733312786099531\ \(0\)\
\-\ tender\\:\\ 0\\.014720817247992646\ \(0\)\
\-\ weakness\\:\\ 0\\.014695958090119778\ \(0\)\
\-\ diagnosed\\:\\ 0\\.014586208758341315\ \(0\)\
\-\ since\\:\\ 0\\.014586208758341315\ \(0\)\
\-\ involvement\\:\\ 0\\.014574222377285537\ \(0\)\
\-\ above\\:\\ 0\\.014526679761951499\ \(0\)\
\-\ early\\:\\ 0\\.014514893487799161\ \(0\)\
\-\ reported\\:\\ 0\\.014503146435929495\ \(0\)\
\-\ mid\\:\\ 0\\.014491438346160805\ \(0\)\
\-\ presence\\:\\ 0\\.014468138025067159\ \(0\)\
\-\ ap\\:\\ 0\\.014456545286144958\ \(0\)\
\-\ peripheral\\:\\ 0\\.014399145877892297\ \(0\)\
\-\ then\\:\\ 0\\.014254133969155034\ \(0\)\
\-\ palpable\\:\\ 0\\.014146504112570351\ \(0\)\
\-\ effect\\:\\ 0\\.014125366409714225\ \(0\)\
\-\ was\\:\\ 0\\.014035416242866706\ \(0\)\
\-\ location\\:\\ 0\\.014021535811754535\ \(0\)\
\-\ sign\\:\\ 0\\.013940615687747205\ \(0\)\
\-\ liver\\:\\ 0\\.013890966686038687\ \(0\)\
\-\ headache\\:\\ 0\\.013881120136197618\ \(0\)\
\-\ this\\:\\ 0\\.013838406805005603\ \(0\)\
\-\ benign\\:\\ 0\\.013832295210806785\ \(0\)\
\-\ 30\\:\\ 0\\.013736625782747432\ \(0\)\
\-\ elevated\\:\\ 0\\.013727199913784476\ \(0\)\
\-\ cause\\:\\ 0\\.013717799147032224\ \(0\)\
\-\ areas\\:\\ 0\\.01367116721620096\ \(0\)\
\-\ possible\\:\\ 0\\.013643480910907701\ \(0\)\
\-\ recent\\:\\ 0\\.013634300188361677\ \(0\)\
\-\ followed\\:\\ 0\\.013597814221894046\ \(0\)\
\-\ study\\:\\ 0\\.013429476854995577\ \(0\)\
\-\ often\\:\\ 0\\.013138949858677237\ \(0\)\
\-\ patient\\:\\ 0\\.013098670378904224\ \(0\)\
\-\ area\\:\\ 0\\.0130446016367921\ \(0\)\
\-\ known\\:\\ 0\\.013036851939213629\ \(0\)\
\-\ mr\\:\\ 0\\.013029119217985177\ \(0\)\
\-\ any\\:\\ 0\\.013013704408209354\ \(0\)\
\-\ resection\\:\\ 0\\.012907645354111015\ \(0\)\
\-\ days\\:\\ 0\\.012747163817858648\ \(0\)\
\-\ age\\:\\ 0\\.012641783280980888\ \(0\)\
\-\ diffuse\\:\\ 0\\.012627967271840394\ \(0\)\
\-\ enhancing\\:\\ 0\\.01261420512642001\ \(0\)\
\-\ only\\:\\ 0\\.012580032683083333\ \(0\)\
\-\ years\\:\\ 0\\.012343296899488357\ \(0\)\
\-\ neck\\:\\ 0\\.012317946802541438\ \(0\)\
\-\ loss\\:\\ 0\\.012267786301984756\ \(0\)\
\-\ lung\\:\\ 0\\.012249158365198942\ \(0\)\
\-\ all\\:\\ 0\\.01198667367628547\ \(0\)\
\-\ time\\:\\ 0\\.011935306767532974\ \(0\)\
\-\ however\\:\\ 0\\.011918349236943807\ \(0\)\
\-\ 10\\:\\ 0\\.011774699319995644\ \(0\)\
\-\ presented\\:\\ 0\\.011742363345828198\ \(0\)\
\-\ been\\:\\ 0\\.01173165017879134\ \(0\)\
\-\ fluid\\:\\ 0\\.011626269641913581\ \(0\)\
\-\ significant\\:\\ 0\\.011626269641913581\ \(0\)\
\-\ lesions\\:\\ 0\\.011564519044016026\ \(0\)\
\-\ these\\:\\ 0\\.011370978731379728\ \(0\)\
\-\ patients\\:\\ 0\\.01132778326042105\ \(0\)\
\-\ prior\\:\\ 0\\.011266308410352342\ \(0\)\
\-\ anterior\\:\\ 0\\.01124294640695304\ \(0\)\
\-\ both\\:\\ 0\\.01122900306099316\ \(0\)\
\-\ none\\:\\ 0\\.01100437348497258\ \(0\)\
\-\ bilateral\\:\\ 0\\.010822003334034781\ \(0\)\
\-\ into\\:\\ 0\\.01070412296319652\ \(0\)\
\-\ noted\\:\\ 0\\.01067624926980148\ \(0\)\
\-\ chest\\:\\ 0\\.010628971967194301\ \(0\)\
\-\ without\\:\\ 0\\.010621153612217056\ \(0\)\
\-\ imaging\\:\\ 0\\.010582319493064343\ \(0\)\
\-\ lower\\:\\ 0\\.010289683340979348\ \(0\)\
\-\ demonstrates\\:\\ 0\\.010116269995058243\ \(0\)\
\-\ surgical\\:\\ 0\\.009786910099957582\ \(0\)\
\-\ after\\:\\ 0\\.009768460654671803\ \(0\)\
\-\ treatment\\:\\ 0\\.00959199938162236\ \(0\)\
\-\ also\\:\\ 0\\.00947154951202297\ \(0\)\
\-\ normal\\:\\ 0\\.008221525892105432\ \(0\)\
\-\ not\\:\\ 0\\.007949341550646133\ \(0\)\
\-\ ct\\:\\ 0\\.007666087437267887\ \(0\)\
\-\ right\\:\\ 0\\.006676024419111996\ \(0\)\
